Conversion to sirolimus immunosuppression in liver transplantation recipients with hepatocellular carcinoma: Report of an initial experience - Wikidata - wikimedia - TriplyDB

Conversion to sirolimus immunosuppression in liver transplantation recipients with hepatocellular carcinoma: Report of an initial experience

Conversion to sirolimus immunosuppression in liver transplantation recipients with hepatocellular carcinoma: Report of an initial experience

http://www.wikidata.org/entity/Q33371289

about

Pilot study: rapamycin in advanced hepatocellular carcinoma.Activation of PI3K/AKT and MAPK pathway through a PDGFRβ-dependent feedback loop is involved in rapamycin resistance in hepatocellular carcinoma.Comparison of steroid-free immunosuppression and standard immunosuppression for liver transplant patients with hepatocellular carcinoma Liver transplantation outcomes in 1,078 hepatocellular carcinoma patients: a multi-center experience in Shanghai, China.Hepatocellular carcinoma following renal transplantation.Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial.Sirolimus and liver transplantation: clinical implications for hepatocellular carcinoma.Strategies for the management of hepatocellular carcinoma.Impact of sirolimus on the recurrence of hepatocellular carcinoma after liver transplantation.Hepatocellular carcinoma and liver transplantation: clinical perspective on molecular targeted strategies.Recurrent hepatocellular carcinoma after liver transplantation - an emerging clinical challenge.Meta-analysis: recurrence and survival following the use of sirolimus in liver transplantation for hepatocellular carcinoma.Laryngeal transplantation in the setting of cancer: a rat model.Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma.Investigating Effect of Rapamycin and Metformin on Angiogenesis in Hepatocellular Carcinoma Cell Line.

P2860

Q33390766-3B695620-D298-48D2-BE68-A9B8B207524D Q34200875-03B961F7-144C-406B-A9D6-27CC805D8CCD Q34937253-F2C25FC5-5DA6-416D-AC0B-F765B8F8C9D5 Q34976928-97729B4F-D6A7-4B0C-B94D-4606987DDED9 Q35715435-4B84D1A4-2491-429C-8AC5-DBDD7D63B281 Q36381360-EB531E04-0C86-42B6-B344-5561C1C7F948 Q36847294-DFD45EB4-B28D-4D43-A960-966A60D86B62 Q36863488-24FCBD21-B634-40CD-A2AF-B9BADFDC9398 Q37638642-935FB9AE-F732-4FCF-B649-57328D08EF57 Q37933157-E44B03F9-99F6-4F9A-BD0C-273C9F3BDE20 Q38045000-5C685241-5305-4B7B-AE00-83942272B682 Q38070693-8DAFD6A9-E444-499F-84E7-733D3C0590C1 Q39925909-2B31F92E-181A-43F1-B150-BA4D9C2B4DF0 Q46715469-8A3B37DB-9F16-4FCF-A7BB-846D650ABF9B Q55286501-404844E0-653C-40D2-849F-8448496AB056

P2860

Conversion to sirolimus immunosuppression in liver transplantation recipients with hepatocellular carcinoma: Report of an initial experience

http://www.wikidata.org/entity/Q33371289

description

2006 nî lūn-bûn

@nan

2006 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Conversion to sirolimus immuno ...... eport of an initial experience

@ast

Conversion to sirolimus immuno ...... eport of an initial experience

@en

type

label

Conversion to sirolimus immuno ...... eport of an initial experience

@ast

Conversion to sirolimus immuno ...... eport of an initial experience

@en

prefLabel

Conversion to sirolimus immuno ...... eport of an initial experience

@ast

Conversion to sirolimus immuno ...... eport of an initial experience

@en

P1433

Q33371289-39A32AA6-CBA0-44CA-9C47-1593F2D5A05B

P1476

Q33371289-B79FDD23-86A6-4512-9738-3820B3071549

P2093

Q33371289-0FF8FCAC-B119-48F6-B522-16FA01059067

Q33371289-1BAC8AF4-7834-4075-93DA-4B6326047953

Q33371289-284764A2-9982-42AE-8072-7E9574ABEDD1

Q33371289-3B156EBD-B02B-460D-8BED-229B7E627A0F

Q33371289-3BC8D095-4EA3-4114-A59D-82BC85285EEB

Q33371289-4D3F6937-B012-4B70-8A8F-C8DE89900985

Q33371289-895DEF2E-3EC1-43E6-A8BB-4A332334E7FC

Q33371289-A322451B-AC04-45E5-818C-A26D064DA27F

Q33371289-E08CF126-9B06-4296-B552-DEFBB2A34BCC

Q33371289-F2B4EC7A-ADCB-4F36-BED3-A973C18D4011

P2860

Q33371289-0FA8C5A8-6737-4601-87E9-2E4319043844

Q33371289-1F9CF0F4-D7A5-4238-A1DD-E5652920BE3A

Q33371289-28E38118-22EE-4656-9134-EA331592FFE9

Q33371289-3ED23078-30D5-4618-9ADB-CB5DF61A8993

Q33371289-457DA58B-B681-44DD-B32B-DC65D8F10D73

Q33371289-57C69B49-14EA-46D2-96E2-2FA7340505BB

Q33371289-61388B83-519D-4F3B-AE69-CF37E2E26783

Q33371289-72005122-2B61-42A3-A924-4ED5C07E95A7

Q33371289-A495BC30-6F1C-41A8-AE06-3A935C2D5CF9

Q33371289-A81E5CCB-F7BD-4582-AE00-373A9D0E7C46

P304

Q33371289-62CD4879-4078-4949-AA72-90749051A48A

P31

Q33371289-82B9D235-03BF-4865-9A3A-76DBC7DD76F8

P356

Q33371289-39E51D33-9600-4E3A-8D6E-0B0721047C30

P407

Q33371289-12A636E6-C586-474C-B37D-1F6365E24F58

P433

Q33371289-F3D68E84-51FD-4BE4-86BC-F8EC0D4D8ED3

P478

Q33371289-972C173A-A626-4A16-BD10-34E8A166C730

P577

Q33371289-71C0F702-8262-4585-B423-860D802DA256

P5875

Q33371289-12863653-46E8-4142-913D-1E877CED05A2

P698

Q33371289-B0D42422-7FFB-420F-9023-393316070B7D

P921

Q33371289-6D6082DC-7F7D-468F-B78F-7F0D6F0EC00C

Q33371289-F6F78997-184B-4DAA-87D0-098A1E584EB4

P932

Q33371289-FAD017C3-1651-4637-B890-4213A2AD0729

P356

WJG.V12.I19.3114

P1433

World Journal of Gastroenterology

P1476

Conversion to sirolimus immuno ...... eport of an initial experience

@en

P2093

Jia Fan

http://www.w3.org/2001/XMLSchema#string

Jian Sun

http://www.w3.org/2001/XMLSchema#string

Jian Zhou

http://www.w3.org/2001/XMLSchema#string

Shuang-Jian Qiu

http://www.w3.org/2001/XMLSchema#string

Xiao-Wu Huang

http://www.w3.org/2001/XMLSchema#string

Yao Yu

http://www.w3.org/2001/XMLSchema#string

Yi-Feng He

http://www.w3.org/2001/XMLSchema#string

Yong-Sheng Xiao

http://www.w3.org/2001/XMLSchema#string

Yu-Qi Wang

http://www.w3.org/2001/XMLSchema#string

Zhao-You Tang

http://www.w3.org/2001/XMLSchema#string

P2860

Mechanisms of resistance to rapamycins

The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: A potential approach to prevention and treatment of posttransplant lymphoproliferative disorders.

Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma.

Sirolimus inhibits growth of human hepatoma cells alone or combined with tacrolimus, while tacrolimus promotes cell growth.

Liver transplantation for hepatocellular carcinoma: comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria.

Effect of systemic cyclosporine on tumor recurrence after liver transplantation in a model of hepatocellular carcinoma.

Mitogenic signaling by substance P and bombesin-like neuropeptide receptors in astrocytic/glial brain tumor-derived cell lines.

Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients.

Orthotopic liver transplantation using low-dose tacrolimus and sirolimus.

Failure of hormone therapy in prostate cancer involves systematic restoration of androgen responsive genes and activation of rapamycin sensitive signaling.

P304

3114-3118

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3748/WJG.V12.I19.3114

http://www.w3.org/2001/XMLSchema#string

P407

P433

19

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P577

2006-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

298737366

http://www.w3.org/2001/XMLSchema#string

P698

16718799

http://www.w3.org/2001/XMLSchema#string

P921

liver transplantation

immunosuppression

P932

4124393

http://www.w3.org/2001/XMLSchema#string